Bree Foster, PhD
Bree Foster is a science writer at Drug Discovery News with over 2 years of experience at Technology Networks, Drug Discovery News, and other scientific marketing agencies. She holds a PhD in comparative and functional genomics from the University of Liverpool and enjoys crafting compelling stories for science.
Articles by Bree Foster, PhD
| 4 min read
Biogen’s $850 million move to secure full global rights to felzartamab highlights a deeper shift in how antibody-driven diseases are being understood and treated.
| 6 min read
Emerging data shows alpha synuclein may be present in the majority of neurodegenerative disease cases, reshaping how clinicians understand dementia and Parkinson’s.
| 5 min read
Developed by NeuroKaire, the blood-based test creates neurons from patient samples and analyzes their response to antidepressants to guide prescribing decisions.
| 3 min read
Preclinical data show a first-in-class transdermal bicarbonate therapy increases tumor pH, reactivates T cells and slows bladder tumor growth in mice.
| 4 min read
Findings from the randomized trial suggest that modulating the tumour microenvironment alongside chemotherapy may offer a new strategy for improving outcomes in pancreatic cancer
| 4 min read
New vaccines, monoclonal antibodies, and oral therapies offer hope against the growing threat of tick-borne infections.
| 3 min read
A first-of-its-kind CAR T treatment helped a woman achieve year-long remission from three severe autoimmune diseases that resisted nine prior therapies.
| 6 min read
Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results.
| 5 min read
Despite missing its primary endpoint, the trial shows a substantial reduction in stage four cancers and earlier detection across multiple tumor types.
| 4 min read
Oral FGFR3-targeted therapies are emerging as a potential step forward, offering more precise, convenient treatment options for children.
| 5 min read
ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer.
| 4 min read
At the Advanced Therapies conference, industry leaders showcased how in vivo CAR T cell and gene delivery innovations could transform accessibility and clinical outcomes.
